UPCOMING SESSIONS in ET

Wed, May 13, 2026

10:00 – 11:00 PM UTC

Amyloidosis Patient Profile: How I Changed My Life for the Better After Receiving an Amyloidosis Diagnosis Alison Keenan Click To Register

UPCOMING SESSIONS in ET

Wed, May 13, 2026 · 10:00 – 11:00 PM UTC

Amyloidosis Patient Profile: How I Changed My Life for the Better After Receiving an Amyloidosis Diagnosis

Alison Keenan

Click To Register

View all sessions

Community Stories

Jan 28, 2026

The “Mixed Phenotype” Mystery: Why Your hATTR Diagnosis Might Only Be Half the Story

Jan 15, 2026

How Rare Cancer Saved My Life

Jan 15, 2026

My Journey with Amyloidosis: Turning Fear into Purpose

Jan 15, 2026

My Amyloid Story Christine Giosa

Jan 13, 2026

A Second Chance at Life: Gurmit’s Story

Jan 12, 2026

My AL Journey

A follow-up model-based study of people taking Attruby in the clinical trial found that higher TTR levels were linked to better survival in people living with ATTR-CM, regardless of other factors.

Jan 12, 2026

Stabilizing the underlying cause of a rare heart condition

Jul 29, 2025

A Legacy of Hope: Alison’s Story

Apr 05, 2025

Confirming the Benefit of SGLT2 Inhibitors in People With ATTR Amyloidosis, with Justin Riley Lam, MD

Apr 02, 2025

Dottie’s Travel Alert for TAVR Patients

1
2
3
4
5
6
7
8
9
…
Next page
Last page

Subscribe to

RNAi Explained

Dr. Bersell explores RNA interference (RNAi) technology and its applications in treating ATTR-CM and ATTR-PN. Learn about mechanism of action, clinical evidence, and patient outcomes.

Learn More

Expert Perspectives on Attruby®

Dr. Barry Trachtenberg and ATTR community members discuss Attruby™ (acoramidis), covering clinical data, patient perspectives, and treatment considerations.

Watch Discussion